{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:59:10Z","timestamp":1789153150479,"version":"build-2803163510"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00467-021-05370-8","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T10:03:27Z","timestamp":1642500207000},"page":"1967-1980","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Thrombotic microangiopathy in children"],"prefix":"10.1007","volume":"37","author":[{"given":"Lilian Monteiro P.","family":"Palma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Helena","family":"Vaisbich-Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Sridharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl L.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4536-7709","authenticated-orcid":false,"given":"Sanjeev","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"5370_CR1","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","volume":"371","author":"JN George","year":"2014","unstructured":"George JN, Nester CM (2014) Syndromes of thrombotic microangiopathy. N Engl J Med 371:654\u2013666","journal-title":"N Engl J Med"},{"issue":"Suppl 11","key":"5370_CR2","first-page":"2","volume":"14","author":"J Laurence","year":"2016","unstructured":"Laurence J, Haller H, Mannucci PM, Nangaku M, Praga M, Rodriguez de Cordoba S (2016) Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin Adv Hematol Oncol 14(Suppl 11):2\u201315","journal-title":"Clin Adv Hematol Oncol"},{"key":"5370_CR3","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/jth.13571","volume":"15","author":"Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, Lammle B, Matsumoto M, Pavenski K, Sadler E, Sarode R, Wu H, International Working Group for Thrombotic Thrombocytopenic Purpura","year":"2017","unstructured":"Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, Lammle B, Matsumoto M, Pavenski K, Sadler E, Sarode R, Wu H, International Working Group for Thrombotic Thrombocytopenic Purpura (2017) Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 15:312\u2013322","journal-title":"J Thromb Haemost"},{"key":"5370_CR4","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1007\/s00134-018-5059-2","volume":"44","author":"BS Joly","year":"2018","unstructured":"Joly BS, Zheng XL, Veyradier A (2018) Understanding thrombotic microangiopathies in children. Intensive Care Med 44:1536\u20131538","journal-title":"Intensive Care Med"},{"key":"5370_CR5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/ckj\/sfz066","volume":"13","author":"U Schonermarck","year":"2020","unstructured":"Schonermarck U, Ries W, Schroppel B, Pape L, Dunaj-Kazmierowska M, Burst V, Mitzner S, Basara N, Starck M, Schmidbauer D, Mellmann A, Dittmer R, Jeglitsch M, Haas CS (2020) Relative incidence of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome in clinically suspected cases of thrombotic microangiopathy. Clin Kidney J 13:208\u2013216","journal-title":"Clin Kidney J"},{"key":"5370_CR6","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1093\/ckj\/sfaa062","volume":"14","author":"Palma LMP, Eick RG, Dantas GC, Tino M, de Holanda MI, Brazilian Thrombotic M, Atypical Hemolytic Uremic Syndrome Study Group","year":"2021","unstructured":"Palma LMP, Eick RG, Dantas GC, Tino M, de Holanda MI, Brazilian Thrombotic M, Atypical Hemolytic Uremic Syndrome Study Group (2021) Atypical hemolytic uremic syndrome in Brazil: clinical presentation, genetic findings and outcomes of a case series in adults and children treated with eculizumab. Clin Kidney J 14:1126\u20131135","journal-title":"Clin Kidney J"},{"key":"5370_CR7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1093\/ckj\/sfz043","volume":"12","author":"MI de Holanda","year":"2019","unstructured":"de Holanda MI, Gomes CP, Araujo SA, Wanderley DC, Eick RG, Dantas GC, Tino M, Pesquero JB, Palma LMP (2019) Diacylglycerol kinase epsilon nephropathy: late diagnosis and therapeutic implications. Clin Kidney J 12:641\u2013644","journal-title":"Clin Kidney J"},{"key":"5370_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00467-001-0783-0","volume":"17","author":"SP Andreoli","year":"2002","unstructured":"Andreoli SP, Trachtman H, Acheson DW, Siegler RL, Obrig TG (2002) Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy. Pediatr Nephrol 17:293\u2013298","journal-title":"Pediatr Nephrol"},{"key":"5370_CR9","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1086\/341940","volume":"186","author":"A Gerber","year":"2002","unstructured":"Gerber A, Karch H, Allerberger F, Verweyen HM, Zimmerhackl LB (2002) Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997\u20132000, in Germany and Austria: a prospective study. J Infect Dis 186:493\u2013500","journal-title":"J Infect Dis"},{"key":"5370_CR10","first-page":"905","volume":"85","author":"C Gasser","year":"1955","unstructured":"Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R (1955) Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia. Schweiz Med Wochenschr 85:905\u2013909","journal-title":"Schweiz Med Wochenschr"},{"key":"5370_CR11","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1007\/s00467-020-04560-0","volume":"35","author":"E Ylinen","year":"2020","unstructured":"Ylinen E, Salmenlinna S, Halkilahti J, Jahnukainen T, Korhonen L, Virkkala T, Rimhanen-Finne R, Nuutinen M, Kataja J, Arikoski P, Linkosalo L, Bai X, Matussek A, Jalanko H, Saxen H (2020) Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli in children: incidence, risk factors, and clinical outcome. Pediatr Nephrol 35:1749\u20131759","journal-title":"Pediatr Nephrol"},{"key":"5370_CR12","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00467-020-04829-4","volume":"36","author":"M Luna","year":"2020","unstructured":"Luna M, Kamariski M, Principi I, Bocanegra V, Valles PG (2020) Severely ill pediatric patients with Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) who suffered from multiple organ involvement in the early stage. Pediatr Nephrol 36:1499\u20131509","journal-title":"Pediatr Nephrol"},{"key":"5370_CR13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.hoc.2015.01.007","volume":"29","author":"LS Keir","year":"2015","unstructured":"Keir LS (2015) Shiga toxin associated hemolytic uremic syndrome. Hematol Oncol Clin North Am 29:525\u2013539","journal-title":"Hematol Oncol Clin North Am"},{"key":"5370_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00467-011-2067-7","volume":"27","author":"MJ Kemper","year":"2012","unstructured":"Kemper MJ (2012) Outbreak of hemolytic uremic syndrome caused by E. coli O104:H4 in Germany: a pediatric perspective. Pediatr Nephrol 27:161\u2013164","journal-title":"Pediatr Nephrol"},{"key":"5370_CR15","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/lam.13295","volume":"70","author":"W Rastawicki","year":"2020","unstructured":"Rastawicki W, Smietanska K, Rokosz-Chudziak N, Wolkowicz T (2020) Antibody response to lipopolysaccharides and recombinant proteins of Shiga toxin (STX)-producing Escherichia coli (STEC) in children with haemolytic uraemic syndrome in Poland. Lett Appl Microbiol 70:440\u2013446","journal-title":"Lett Appl Microbiol"},{"key":"5370_CR16","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1007\/s00467-020-04697-y","volume":"35","author":"G Ardissino","year":"2020","unstructured":"Ardissino G, Possenti I, Vignati C, Daprai L, Capone V, Brigotti M, Luini MV, Consonni D, Montini G (2020) Is Shigatoxin 1 protective for the development of Shigatoxin 2-related hemolytic uremic syndrome in children? Data from the ItalKid-HUS Network. Pediatr Nephrol 35:1997\u20132001","journal-title":"Pediatr Nephrol"},{"key":"5370_CR17","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1007\/s00467-018-4105-1","volume":"34","author":"M Khalid","year":"2019","unstructured":"Khalid M, Andreoli S (2019) Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS). Pediatr Nephrol 34:2495\u20132507","journal-title":"Pediatr Nephrol"},{"key":"5370_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3389\/fmed.2020.00357","volume":"7","author":"GS Netti","year":"2020","unstructured":"Netti GS, Santangelo L, Paulucci L, Piscopo G, Torres DD, Carbone V, Giordano P, Spadaccino F, Castellano G, Stallone G, Gesualdo L, Chironna M, Ranieri E, Giordano M (2020) Low C3 serum levels predict severe forms of STEC-HUS with neurologic involvement. Front Med (Lausanne) 7:357","journal-title":"Front Med (Lausanne)"},{"key":"5370_CR19","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00467-019-04334-3","volume":"35","author":"A Balestracci","year":"2020","unstructured":"Balestracci A, MeniBataglia L, Toledo I, Beaudoin L, Alvarado C (2020) C3 levels and acute outcomes in Shiga toxin-related hemolytic uremic syndrome. Pediatr Nephrol 35:331\u2013339","journal-title":"Pediatr Nephrol"},{"key":"5370_CR20","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00467-016-3496-0","volume":"32","author":"D Westra","year":"2017","unstructured":"Westra D, Volokhina EB, van der Molen RG, van der Velden TJ, Jeronimus-Klaasen A, Goertz J, Gracchi V, Dorresteijn EM, Bouts AH, Keijzer-Veen MG, van Wijk JA, Bakker JA, Roos A, van den Heuvel LP, van de Kar NC (2017) Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Pediatr Nephrol 32:297\u2013309","journal-title":"Pediatr Nephrol"},{"key":"5370_CR21","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrneph.2012.195","volume":"8","author":"M Noris","year":"2012","unstructured":"Noris M, Mescia F, Remuzzi G (2012) STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 8:622\u2013633","journal-title":"Nat Rev Nephrol"},{"key":"5370_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/toxins12020067","volume":"12","author":"A Joseph","year":"2020","unstructured":"Joseph A, Cointe A, MarianiKurkdjian P, Rafat C, Hertig A (2020) Shiga Toxin-associated hemolytic uremic syndrome: a narrative review. Toxins (Basel) 12:67","journal-title":"Toxins (Basel)"},{"key":"5370_CR23","first-page":"39","volume":"119","author":"LI Lucarelli","year":"2021","unstructured":"Lucarelli LI, Alconcher LF, Arias V, Galavotti J (2021) Duration of fecal shedding of Shiga toxin-producing Escherichia coli among children with hemolytic uremic syndrome. Arch Argent Pediatr 119:39\u201343","journal-title":"Arch Argent Pediatr"},{"key":"5370_CR24","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00467-018-4118-9","volume":"34","author":"KL Wijnsma","year":"2019","unstructured":"Wijnsma KL, Veissi ST, van Bommel SAM, Heuver R, Volokhina EB, Comerci DJ, Ugalde JE, van de Kar N, van den Heuvel L (2019) Glyco-iELISA: a highly sensitive and unambiguous serological method to diagnose STEC-HUS caused by serotype O157. Pediatr Nephrol 34:631\u2013639","journal-title":"Pediatr Nephrol"},{"key":"5370_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/20469047.2019.1616458","volume":"40","author":"ME Celakil","year":"2020","unstructured":"Celakil ME, Yucel BB, Bek K (2020) CFH and CFB mutations in Shiga toxin-associated haemolytic uraemic syndrome in a 6-year-old boy. Paediatr Int Child Health 40:129\u2013131","journal-title":"Paediatr Int Child Health"},{"key":"5370_CR26","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/infdis\/151.5.775","volume":"151","author":"MA Karmali","year":"1985","unstructured":"Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H (1985) The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 151:775\u2013782","journal-title":"J Infect Dis"},{"key":"5370_CR27","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/toxins12070435","volume":"12","author":"EB Volokhina","year":"2020","unstructured":"Volokhina EB, Feitz WJC, Elders LM, van der Velden T, van de Kar N, van den Heuvel L (2020) Shiga toxin selectively upregulates expression of syndecan-4 and adhesion molecule ICAM-1 in human glomerular microvascular endothelium. Toxins (Basel) 12:435","journal-title":"Toxins (Basel)"},{"key":"5370_CR28","doi-asserted-by":"publisher","unstructured":"Ardissino G, Tel F, Possenti I, Testa S, Consonni D, Paglialonga F, Salardi S, Borsa-Ghiringhelli N, Salice P, Tedeschi S, Castorina P, Colombo RM, Arghittu M, Daprai L, Monzani A, Tozzoli R, Brigotti M, Torresani E (2016) Early volume expansion and outcomes of hemolytic uremic syndrome. Pediatrics 137(1). https:\/\/doi.org\/10.1542\/peds.2015-2153","DOI":"10.1542\/peds.2015-2153"},{"key":"5370_CR29","doi-asserted-by":"publisher","first-page":"e4565","DOI":"10.1136\/bmj.e4565","volume":"345","author":"J Menne","year":"2012","unstructured":"Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, Bremer JP, Brunkhorst R, Busch V, Dengler R, Deuschl G, Fellermann K, Fickenscher H, Gerigk C, Goettsche A, Greeve J, Hafer C, Hagenmuller F, Haller H, Herget-Rosenthal S, Hertenstein B, Hofmann C, Lang M, Kielstein JT, Klostermeier UC, Knobloch J, Kuehbacher M, Kunzendorf U, Lehnert H, Manns MP, Menne TF, Meyer TN, Michael C, Munte T, Neumann-Grutzeck C, Nuernberger J, Pavenstaedt H, Ramazan L, Renders L, Repenthin J, Ries W, Rohr A, Rump LC, Samuelsson O, Sayk F, Schmidt BM, Schnatter S, Schocklmann H, Schreiber S, von Seydewitz CU, Steinhoff J, Stracke S, Suerbaum S, van de Loo A, Vischedyk M, Weissenborn K, Wellhoner P, Wiesner M, Zeissig S, Buning J, Schiffer M, Kuehbacher T, EHEC-HUS consortium, (2012) Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 345:e4565","journal-title":"BMJ"},{"key":"5370_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12882-019-1314-1","volume":"20","author":"J Menne","year":"2019","unstructured":"Menne J, Delmas Y, Fakhouri F, Licht C, Lommele A, Minetti EE, Provot F, Rondeau E, Sheerin NS, Wang J, Weekers LE, Greenbaum LA (2019) Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrol 20:125","journal-title":"BMC Nephrol"},{"key":"5370_CR31","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/1744-9987.12768","volume":"23","author":"W Keenswijk","year":"2019","unstructured":"Keenswijk W, Raes A, De Clerck M, Vande Walle J (2019) Is plasma exchange efficacious in shiga toxin-associated hemolytic uremic syndrome? A Narrative Review of Current Evidence. Ther Apher Dial 23:118\u2013125","journal-title":"Ther Apher Dial"},{"key":"5370_CR32","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1093\/ndt\/gfz158","volume":"35","author":"C Monet-Didailler","year":"2020","unstructured":"Monet-Didailler C, Chevallier A, Godron-Dubrasquet A, Allard L, Delmas Y, Contin-Bordes C, Brissaud O, Llanas B, Harambat J (2020) Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study. Nephrol Dial Transplant 35:2147\u20132153","journal-title":"Nephrol Dial Transplant"},{"key":"5370_CR33","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00467-018-4025-0","volume":"34","author":"PR Walsh","year":"2019","unstructured":"Walsh PR, Johnson S (2019) Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol 34:1485\u20131492","journal-title":"Pediatr Nephrol"},{"key":"5370_CR34","first-page":"5587050","volume":"2021","author":"C Rosazza","year":"2021","unstructured":"Rosazza C, Cappellari AM, Gandini C, Scola E, Ardissino G (2021) Steroid pulse therapy for severe central nervous system involvement in shiga toxin-producing Escherichia coli-related hemolytic uremic syndrome. Case Rep Pediatr 2021:5587050","journal-title":"Case Rep Pediatr"},{"key":"5370_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jinf.2019.05.018","volume":"79","author":"L Kakoullis","year":"2019","unstructured":"Kakoullis L, Papachristodoulou E, Chra P, Panos G (2019) Shiga toxin-induced haemolytic uraemic syndrome and the role of antibiotics: a global overview. J Infect 79:75\u201394","journal-title":"J Infect"},{"key":"5370_CR36","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.3390\/ijerph16091649","volume":"16","author":"M Giordano","year":"2019","unstructured":"Giordano M, Baldassarre ME, Palmieri V, Torres DD, Carbone V, Santangelo L, Gentile F, Panza R, Di Mauro F, Capozza M, Di Mauro A, Laforgia N (2019) Management of STEC gastroenteritis: is there a role for probiotics? Int J Environ Res Public Health 16:1649","journal-title":"Int J Environ Res Public Health"},{"key":"5370_CR37","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.3390\/jcm10143034","volume":"10","author":"S Timmermans","year":"2021","unstructured":"Timmermans S, van Paassen P (2021) The syndromes of thrombotic microangiopathy: a critical appraisal on complement dysregulation. J Clin Med 10:3034","journal-title":"J Clin Med"},{"key":"5370_CR38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/qjmed\/hcv082","volume":"109","author":"NS Sheerin","year":"2016","unstructured":"Sheerin NS, Kavanagh D, Goodship TH, Johnson S (2016) A national specialized service in England for atypical haemolytic uraemic syndrome-the first year\u2019s experience. QJM 109:27\u201333","journal-title":"QJM"},{"key":"5370_CR39","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s10157-017-1478-6","volume":"22","author":"RW Thergaonkar","year":"2018","unstructured":"Thergaonkar RW, Narang A, Gurjar BS, Tiwari P, Puraswani M, Saini H, Sinha A, Varma B, Mukerji M, Hari P, Bagga A (2018) Targeted exome sequencing in anti-factor H antibody negative HUS reveals multiple variations. Clin Exp Nephrol 22:653\u2013660","journal-title":"Clin Exp Nephrol"},{"key":"5370_CR40","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s10157-018-1610-2","volume":"23","author":"S Ito","year":"2018","unstructured":"Ito S, Hidaka Y, Inoue N, Kaname S, Kato H, Matsumoto M, Miyakawa Y, Mizuno M, Okada H, Shimono A, Matsuda T, Maruyama S, Fujimura Y, Nangaku M, Kagami S (2018) Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clin Exp Nephrol 23:112\u2013121","journal-title":"Clin Exp Nephrol"},{"key":"5370_CR41","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","volume":"390","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C (2017) Haemolytic uraemic syndrome. Lancet 390:681\u2013696","journal-title":"Lancet"},{"key":"5370_CR42","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1056\/NEJMra1312353","volume":"371","author":"JN George","year":"2014","unstructured":"George JN, Nester CM (2014) Syndromes of thrombotic microangiopathy. N Engl J Med 371:1847\u20131848","journal-title":"N Engl J Med"},{"key":"5370_CR43","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:1844\u20131859","journal-title":"Clin J Am Soc Nephrol"},{"key":"5370_CR44","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1681\/ASN.2006080811","volume":"18","author":"Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C, French Society of Pediatric Nephrology","year":"2007","unstructured":"Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C, French Society of Pediatric Nephrology (2007) Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 18:2392\u20132400","journal-title":"J Am Soc Nephrol"},{"key":"5370_CR45","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1681\/ASN.2012090884","volume":"24","author":"E Bresin","year":"2013","unstructured":"Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M, European Working Party on Complement Genetics in Renal Diseases (2013) Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 24:475\u2013486","journal-title":"J Am Soc Nephrol"},{"key":"5370_CR46","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.kint.2018.02.029","volume":"94","author":"F Schaefer","year":"2018","unstructured":"Schaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N, Lommele A, Kupelian V, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Licht C, Vande Walle J, Fremeaux-Bacchi V, Global aHUS Registry, (2018) Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int 94:408\u2013418","journal-title":"Kidney Int"},{"key":"5370_CR47","first-page":"110","volume":"46","author":"RA Thompson","year":"1981","unstructured":"Thompson RA, Winterborn MH (1981) Hypocomplementaemia due to a genetic deficiency of beta 1H globulin. Clin Exp Immunol 46:110\u2013119","journal-title":"Clin Exp Immunol"},{"key":"5370_CR48","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/j.1523-1755.1998.00824.x","volume":"53","author":"P Warwicker","year":"1998","unstructured":"Warwicker P, Goodship TH, Donne RL, Pirson Y, Nicholls A, Ward RM, Turnpenny P, Goodship JA (1998) Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 53:836\u2013844","journal-title":"Kidney Int"},{"key":"5370_CR49","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","volume":"91","author":"TH Goodship","year":"2017","unstructured":"Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodriguez de Cordoba S, Roumenina LT, Sethi S, Smith RJH, Participants C (2017) Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: improving global outcomes\u201d (KDIGO) Controversies Conference. Kidney Int 91:539\u2013551","journal-title":"Kidney Int"},{"key":"5370_CR50","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschenes G, Lebranchu Y, Zuber J, Loirat C (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8:554\u2013562","journal-title":"Clin J Am Soc Nephrol"},{"key":"5370_CR51","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/ajt.12077","volume":"13","author":"M Le Quintrec","year":"2013","unstructured":"Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, Chatelet V, Mousson C, Mourad G, Bridoux F, Cassuto E, Loirat C, Rondeau E, Delahousse M, Fremeaux-Bacchi V (2013) Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 13:663\u2013675","journal-title":"Am J Transplant"},{"key":"5370_CR52","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nurnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169\u20132181","journal-title":"N Engl J Med"},{"key":"5370_CR53","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C (2015) Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87:1061\u20131073","journal-title":"Kidney Int"},{"key":"5370_CR54","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","volume":"68","author":"F Fakhouri","year":"2016","unstructured":"Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provot F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM (2016) Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis 68:84\u201393","journal-title":"Am J Kidney Dis"},{"key":"5370_CR55","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C (2016) Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89:701\u2013711","journal-title":"Kidney Int"},{"key":"5370_CR56","first-page":"39","volume":"7","author":"LM Palma","year":"2016","unstructured":"Palma LM, Langman CB (2016) Critical appraisal of eculizumab for atypical hemolytic uremic syndrome. J Blood Med 7:39\u201372","journal-title":"J Blood Med"},{"key":"5370_CR57","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.2215\/CJN.01090209","volume":"4","author":"CJ Mache","year":"2009","unstructured":"Mache CJ, Acham-Roschitz B, Fremeaux-Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E (2009) Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 4:1312\u20131316","journal-title":"Clin J Am Soc Nephrol"},{"key":"5370_CR58","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood.2020009280","volume":"137","author":"F Fakhouri","year":"2020","unstructured":"Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc AL, Ville S, Pouteil-Noble C, Coindre JP, Le Quintrec M, Rondeau E, Boyer O, Provot F, Djeddi D, Hanf W, Delmas Y, Louillet F, Lahoche A, Favre G, Chatelet V, Allain-Launay E, Presne C, Zaloszyc A, Caillard S, Bally S, Raimbourg Q, Tricot L, Mousson C, Le Thuaut A, Loirat C, Fremeaux-Bacchi V (2020) Eculizumab discontinuation in children and adults with atypical haemolytic uremic syndrome: a prospective multicentric study. Blood 137:2438\u20132449","journal-title":"Blood"},{"key":"5370_CR59","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","volume":"97","author":"E Rondeau","year":"2020","unstructured":"Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H (2020) The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment. Kidney Int 97:1287\u20131296","journal-title":"Kidney Int"},{"key":"5370_CR60","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.kint.2020.10.046","volume":"100","author":"Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA; 312 Study Group","year":"2021","unstructured":"Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA; 312 Study Group (2021) The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment. Kidney Int 100:225\u2013237","journal-title":"Kidney Int"},{"key":"5370_CR61","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s00467-019-04342-3","volume":"35","author":"RR Scobell","year":"2020","unstructured":"Scobell RR, Kaplan BS, Copelovitch L (2020) New insights into the pathogenesis of Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Nephrol 35:1585\u20131591","journal-title":"Pediatr Nephrol"},{"key":"5370_CR62","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jpeds.2007.03.055","volume":"151","author":"AM Waters","year":"2007","unstructured":"Waters AM, Kerecuk L, Luk D, Haq MR, Fitzpatrick MM, Gilbert RD, Inward C, Jones C, Pichon B, Reid C, Slack MP, Van\u2019t Hoff W, Dillon MJ, Taylor CM, Tullus K (2007) Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United kingdom experience. J Pediatr 151:140\u2013144","journal-title":"J Pediatr"},{"key":"5370_CR63","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1542\/peds.101.4.699","volume":"101","author":"GR Cabrera","year":"1998","unstructured":"Cabrera GR, Fortenberry JD, Warshaw BL, Chambliss CR, Butler JC, Cooperstone BG (1998) Hemolytic uremic syndrome associated with invasive Streptococcus pneumoniae infection. Pediatrics 101:699\u2013703","journal-title":"Pediatrics"},{"key":"5370_CR64","first-page":"183","volume":"82","author":"RO von Vigier","year":"1999","unstructured":"von Vigier RO, Seibel K, Bianchetti MG (1999) Positive coombs test in pneumococcus-associated hemolytic uremic syndrome. A review of the literature Nephron 82:183\u2013184","journal-title":"A review of the literature Nephron"},{"key":"5370_CR65","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/S0140-6736(77)92915-4","volume":"2","author":"PJ Klein","year":"1977","unstructured":"Klein PJ, Bulla M, Newman RA, Muller P, Uhlenbruck G, Schaefer HE, Kruger G, Fisher R (1977) Thomsen-Friedenreich antigen in haemolytic-uraemic syndrome. Lancet 2:1024\u20131025","journal-title":"Lancet"},{"key":"5370_CR66","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s004670050069","volume":"14","author":"BH Ault","year":"2000","unstructured":"Ault BH (2000) Factor H and the pathogenesis of renal diseases. Pediatr Nephrol 14:1045\u20131053","journal-title":"Pediatr Nephrol"},{"key":"5370_CR67","doi-asserted-by":"publisher","first-page":"e28589","DOI":"10.1002\/pbc.28589","volume":"68","author":"J See","year":"2021","unstructured":"See J, BouMatar R, Baloglu O, Latifi SQ, Talati R, Agarwal HS (2021) Early initiation of eculizumab therapy for Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Blood Cancer 68:e28589","journal-title":"Pediatr Blood Cancer"},{"key":"5370_CR68","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1756-8722-1-23","volume":"1","author":"M Levandovsky","year":"2008","unstructured":"Levandovsky M, Harvey D, Lara P, Wun T (2008) Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients. J Hematol Oncol 1:23","journal-title":"J Hematol Oncol"},{"key":"5370_CR69","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","volume":"4","author":"PK Bendapudi","year":"2017","unstructured":"Bendapudi PK, Hurwitz S, Fry A, Marques MB, Waldo SW, Li A, Sun L, Upadhyay V, Hamdan A, Brunner AM, Gansner JM, Viswanathan S, Kaufman RM, Uhl L, Stowell CP, Dzik WH, Makar RS (2017) Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol 4:e157\u2013e164","journal-title":"Lancet Haematol"},{"key":"5370_CR70","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJM198212023072306","volume":"307","author":"JL Moake","year":"1982","unstructured":"Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin D (1982) Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307:1432\u20131435","journal-title":"N Engl J Med"},{"key":"5370_CR71","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1182\/asheducation-2004.1.407","volume":"2004","author":"JE Sadler","year":"2004","unstructured":"Sadler JE, Moake JL, Miyata T, George JN (2004) Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2004:407\u2013423","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"5370_CR72","doi-asserted-by":"publisher","first-page":"11065","DOI":"10.1021\/bi0204692","volume":"41","author":"DW Chung","year":"2002","unstructured":"Chung DW, Fujikawa K (2002) Processing of von Willebrand factor by ADAMTS-13. Biochemistry 41:11065\u201311070","journal-title":"Biochemistry"},{"key":"5370_CR73","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1111\/j.1538-7836.2005.01360.x","volume":"3","author":"JF Dong","year":"2005","unstructured":"Dong JF (2005) Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost 3:1710\u20131716","journal-title":"J Thromb Haemost"},{"key":"5370_CR74","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.3390\/jcm9103379","volume":"9","author":"I Mancini","year":"2020","unstructured":"Mancini I, Giacomini E, Pontiggia S, Artoni A, Ferrari B, Pappalardo E, Gualtierotti R, Trisolini SM, Capria S, Facchini L, Codeluppi K, Rinaldi E, Pastore D, Campus S, Caria C, Caddori A, Nicolosi D, Giuffrida G, Agostini V, Roncarati U, Mannarella C, Fragasso A, Podda GM, Birocchi S, Cerbone AM, Tufano A, Menna G, Pizzuti M, Ronchi M, De Fanti A, Amarri S, Defina M, Bocchia M, Ceru S, Gattillo S, Rosendaal FR, Peyvandi F (2020) The HLA variant rs6903608 is associated with disease onset and relapse of immune-mediated thrombotic thrombocytopenic purpura in caucasians. J Clin Med 9:3379","journal-title":"J Clin Med"},{"key":"5370_CR75","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1056\/NEJM199108083250605","volume":"325","author":"WR Bell","year":"1991","unstructured":"Bell WR, Braine HG, Ness PM, Kickler TS (1991) Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 325:398\u2013403","journal-title":"N Engl J Med"},{"key":"5370_CR76","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jca.21705","volume":"34","author":"A Padmanabhan","year":"2019","unstructured":"Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ (2019) Guidelines on the use of therapeutic apheresis in clinical practice\u2014evidence-based approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher 34:171\u2013354","journal-title":"J Clin Apher"},{"key":"5370_CR77","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJM199108083250604","volume":"325","author":"GA Rock","year":"1991","unstructured":"Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325:393\u2013397","journal-title":"N Engl J Med"},{"key":"5370_CR78","doi-asserted-by":"publisher","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","volume":"3","author":"JA Kremer Hovinga","year":"2017","unstructured":"Kremer Hovinga JA, Coppo P, Lammle B, Moake JL, Miyata T, Vanhoorelbeke K (2017) Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers 3:17020","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 1","key":"5370_CR79","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1423-0410.1998.tb05474.x","volume":"74","author":"L Biesert","year":"1998","unstructured":"Biesert L, Suhartono H (1998) Solvent\/detergent treatment of human plasma\u2014a very robust method for virus inactivation. Validated virus safety of OCTAPLAS. Vox Sang 74(Suppl 1):207\u2013212","journal-title":"Vox Sang"},{"key":"5370_CR80","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1505533","volume":"374","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knobl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D, TITAN Investigators (2016) Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 374:511\u2013522","journal-title":"N Engl J Med"},{"key":"5370_CR81","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","volume":"380","author":"M Scully","year":"2019","unstructured":"Scully M, Cataland SR, Peyvandi F, Coppo P, Knobl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK,  HERCULES Investigators (2019) Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 380:335\u2013346","journal-title":"N Engl J Med"},{"key":"5370_CR82","first-page":"709","volume":"118","author":"WA Hassenpflug","year":"2018","unstructured":"Hassenpflug WA, Obser T, Bode J, Oyen F, Budde U, Schneppenheim S, Schneppenheim R, Brehm MA (2018) Genetic and functional characterization of ADAMTS13 variants in a patient cohort with Upshaw-Schulman syndrome investigated in Germany. Thromb Haemost 118:709\u2013722","journal-title":"Thromb Haemost"},{"key":"5370_CR83","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1055\/a-1282-2264","volume":"40","author":"JA Kremer Hovinga","year":"2020","unstructured":"Kremer Hovinga JA, Braschler TR, Buchkremer F, Farese S, Hengartner H, Lovey PY, Largiader CR, Mansouri Taleghani B, Tarasco E (2020) Insights from the hereditary thrombotic thrombocytopenic purpura registry: discussion of key findings based on individual cases from Switzerland. Hamostaseologie 40:S5\u2013S14","journal-title":"Hamostaseologie"},{"key":"5370_CR84","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","volume":"31","author":"Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, Vivarelli M, Fremeaux-Bacchi V, HUS International","year":"2016","unstructured":"Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, Vivarelli M, Fremeaux-Bacchi V, HUS International (2016) An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31:15\u201339","journal-title":"Pediatr Nephrol"},{"key":"5370_CR85","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00467-017-3615-6","volume":"32","author":"MH Vaisbich","year":"2017","unstructured":"Vaisbich MH, Braga A, Gabrielle M, Bueno C, Piazzon F, Kok F (2017) Thrombotic microangiopathy caused by methionine synthase deficiency: diagnosis and treatment pitfalls. Pediatr Nephrol 32:1089\u20131092","journal-title":"Pediatr Nephrol"},{"key":"5370_CR86","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1053\/j.ajkd.2013.08.031","volume":"63","author":"E Cornec-Le Gall","year":"2014","unstructured":"Cornec-Le Gall E, Delmas Y, De Parscau L, Doucet L, Ogier H, Benoist JF, Fremeaux-Bacchi V, Le Meur Y (2014) Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. Am J Kidney Dis 63:119\u2013123","journal-title":"Am J Kidney Dis"},{"key":"5370_CR87","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(15)00076-8","volume":"386","author":"S Grange","year":"2015","unstructured":"Grange S, Bekri S, Artaud-Macari E, Francois A, Girault C, Poitou AL, Benhamou Y, Vianey-Saban C, Benoist JF, Chatelet V, Tamion F, Guerrot D (2015) Adult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency. Lancet 386:1011\u20131012","journal-title":"Lancet"},{"key":"5370_CR88","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/ng.2590","volume":"45","author":"M Lemaire","year":"2013","unstructured":"Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, Fakhouri F, Taque S, Nobili F, Martinez F, Ji W, Overton JD, Mane SM, Nurnberg G, Altmuller J, Thiele H, Morin D, Deschenes G, Baudouin V, Llanas B, Collard L, Majid MA, Simkova E, Nurnberg P, Rioux-Leclerc N, Moeckel GW, Gubler MC, Hwa J, Loirat C, Lifton RP (2013) Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 45:531\u2013536","journal-title":"Nat Genet"},{"key":"5370_CR89","doi-asserted-by":"publisher","first-page":"103953","DOI":"10.1016\/j.ejmg.2020.103953","volume":"63","author":"M Bezdicka","year":"2020","unstructured":"Bezdicka M, Pavlicek P, Blahova K, Hacek J, Zieg J (2020) Various phenotypes of disease associated with mutated DGKE gene. Eur J Med Genet 63:103953","journal-title":"Eur J Med Genet"},{"key":"5370_CR90","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/ng.2622","volume":"45","author":"SE Quaggin","year":"2013","unstructured":"Quaggin SE (2013) DGKE and atypical HUS. Nat Genet 45:475\u2013476","journal-title":"Nat Genet"},{"key":"5370_CR91","first-page":"421","volume":"35","author":"JM Campistol","year":"2015","unstructured":"Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyo JM, Macia M, Mendizabal S, Praga M, Roman E, Torra R, Valdes F, Vilalta R, Rodriguez de Cordoba S (2015) An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document Nefrologia 35:421\u2013447","journal-title":"A consensus document Nefrologia"},{"key":"5370_CR92","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/bjh.16457","volume":"189","author":"N Epperla","year":"2020","unstructured":"Epperla N, Li A, Logan B, Fretham C, Chhabra S, Aljurf M, Chee L, Copelan E, Freytes CO, Hematti P, Lazarus HM, Litzow M, Nishihori T, Olsson RF, Prestidge T, Saber W, Wirk B, Yared JA, Loren A, Pasquini M (2020) Incidence, risk factors for and outcomes of transplant-associated thrombotic microangiopathy. Br J Haematol 189:1171\u20131181","journal-title":"Br J Haematol"},{"key":"5370_CR93","first-page":"1049","volume":"135","author":"S Jodele","year":"2020","unstructured":"Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC, Wallace G, Nelson A, Bleesing J, Chima RS, Hirsch R, Ryan TD, Benoit S, Mizuno K, Warren M, Davies SM (2020) Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood 135:1049\u20131057","journal-title":"Blood"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-05370-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-021-05370-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-05370-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T11:01:42Z","timestamp":1744196502000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-021-05370-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":93,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["5370"],"URL":"https:\/\/doi.org\/10.1007\/s00467-021-05370-8","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"assertion":[{"value":"30 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LMPP is a speaker for Alexion Brazil, and scientific consultant for Apellis and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}